Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JX3U | ISIN: US8684591089 | Ticker-Symbol: S49
Frankfurt
06.06.25 | 08:01
28,200 Euro
0,00 % 0,000
1-Jahres-Chart
SUPERNUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SUPERNUS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
29,00029,20006.06.
29,00029,20006.06.

Aktuelle News zur SUPERNUS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.05.Supernus Pharmaceuticals, Inc.: Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree Content Series with Supernus Pharmaceuticals1
SUPERNUS Aktie jetzt für 0€ handeln
28.05.Supernus Pharmaceuticals, Inc.: Supernus Announces Paragraph IV ANDA Filings for Qelbree2
28.05.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report1
21.05.Supernus casts Busy Philipps as 'Ms. Represented' in Qelbree campaign targeting women with ADHD2
20.05.Supernus Pharmaceuticals, Inc.: Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being 'Ms. Represented' in First-of-its-Kind Campaign with Supernus Pharmaceuticals1
07.05.Supernus projects $600M-$630M revenue for 2025 with robust growth in core products1
06.05.SUPERNUS PHARMACEUTICALS, INC. - 10-Q, Quarterly Report-
06.05.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report1
06.05.Supernus Pharmaceuticals, Inc.: Supernus Announces First Quarter 2025 Financial Results80First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the...
► Artikel lesen
05.05.Uncovering Potential: Supernus Pharmaceuticals' Earnings Preview1
30.04.SA analyst downgrades: TSLA, TXN, ORLY, SUPN, KDP13
23.04.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report2
26.02.Cantor maintains neutral on Supernus, price target at $361
25.02.Supernus Pharmaceuticals, Inc.: Supernus Announces Fourth Quarter and Full Year 2024 Financial Results517Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full...
► Artikel lesen
25.02.SUPERNUS PHARMACEUTICALS, INC. - 10-K, Annual Report-
25.02.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report-
19.02.Supernus's stock sinks after depression drug fails trial1
19.02.Sanofi reaches consumer health deal; Supernus antidepressant fails study7
19.02.Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial2
19.02.Supernus reports less than super data for depression drug-
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1